30% would shop elsewhere after a bad chatbot experience, 61% would return after a good experienceRead more...
In three years, Chrome could easily be the leading browser in certain communities
The news that Google is turning its Chrome browser into a full blown linux-based operating system for netbooks has the tech industry buzzing. There's so much to like about this story; Google vs Microsoft, Google vs Apple, the rise of netbooks, the browser as an OS, freeconomics at work in the OS market, etc, etc.
I'm not going to add much to the discussion, particularly almost a full day after the news hit and literally hundreds of blog posts later. But I did enjoy Fake Steve Jobs' rant even though it was toungue in cheek. Fake Steve lists eight reasons why Chrome OS is "no big deal" including this one:
Well that got me thinking if I knew anyone who uses Chrome, and I immediately thought of this community here at AVC. Well guess what, 9% of you all use Chrome. Chrome comes in fourth in this community after Firefox at roughly 50%, IE and Safari basically tied at 18%, and Chrome almost gets double digits. Here's the exact numbers for the past 30 days:
Of course these numbers come from Google Analytics, but I trust Google not to mess around with this stuff.
What's even more interesting is to go back just three years and look at what the browser market share in this community was.
IE had 63%
Firefox had 28%
Safari had 6%
So in just three years, this community's use of IE has gone from 63% to 18%, Firefox has gone from 28% to almost 50%, and Safari has tripled from 6% to 18%.
So Chrome may be under 10% right now, but in three years, it could easily be the leading browser in this community. Browsers apparently don't command that much loyalty and switching costs are low. That said, I'm not moving to Chrome unless I can take my Firefox extensions with me.
(For more from Fred, visit his blog)
(Image source: i-nz.net)
Support VatorNews by Donating
Read more from our "Trends and news" series
The bot will provide education, while also flagging potential problems before they become seriousRead more...
The company, fresh off a $4M round, looks to bring tech to treatment for chronic autoimmune diseaseRead more...